Background: The prevalence of anaemia in IBD varies significantly between published studies, ranging from 6 74%. However, underlying disease activity, a potential explanation for this variability, has not been accurately correlated with the frequency of anaemia to date. Faecal calprotectin (FC) is a surrogate marker of underlying mucosal inflammation. The objective of this study was to investigate the prevalence of anaemia and its correlation with disease activity in IBD, in a large cohort of patients with matched full blood count (FBC) and FC data. Methods: Patients with confirmed IBD from the Edinburgh faecal calprotectin registry (EFCR) were identified. Where multiple FCs were available, the most recent result was taken as reference. Blood test results were obtained from the electronic record covering a period one month either side of the FC. The WHO criteria, as adopted by ECCO, was used to define anaemia (Hb <130 g/L in men, <120 g/L in women). A FC value of 200 mg/g was used to indicate active disease. The cohort was subdivided into 4 groups: active and inactive CD, active and inactive UC. Results: 1226 patients (771 CD, F = 65%, 455 UC, F = 35%) with matched FC and FBC data were analysed. The median age was 44y (IQR 31 57), median disease duration 102 months (IQR 31 207 ], p < 0.0001). The prevalence of anaemia in active UC was greater than in active CD (p = 0.014); however, this could be explained by the higher median FC in the UC cohort (900 vs. 618, p < 0.0001). There was no statistically significant difference in age or Montreal location (L1+L3 vs L2, p = 0.16) between the groups. ROC analysis of FC as a predictor of anaemia showed an AUC of 0.69 with a sensitivity and specificity of 0.73 and 0.57 respectively at a cut off of 200 mg/g. Conclusions: In this cohort over 25% of patients with IBD were anaemic. There is a clear correlation between disease activity and anaemia in both CD and UC but this is unrelated to disease distribution in CD. Anaemia in asymptomatic patients should alert clinicians to the possibility of subclinical active mucosal inflammation. These data and the ROC analysis provide further support for optimising disease treatment in IBD targeting a FC level of <200 mg/g.
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Effectiveness of leukocyte adsorber LA25 in the treatment of inflammatory bowel disease (IBD) patients non-responder to conventional therapy: pilot study LEUKOSMART Background: Depression and anxiety are highly prevalent in patients with inflammatory bowel disease (IBD). Recent studies have linked mental health co-morbidities with active disease, more frequent disease flares and increased hospitalisation. Studies also demonstrate poor treatment compliance in IBD sufferers with unmanaged mental health problems. However, there is a controversy on which treatment modalities are most effective to manage depression and anxiety in IBD and thus this paper aims to review most up-to-date data on psychotherapy and antidepressants in IBD. Methods: A review of the evidence-base for psychotherapy and antidepressant use based on studies from various groups worldwide and ongoing trials conducted in Adelaide, Australia. Results: Studies demonstrate the need for screening for depression and anxiety in IBD as part of standard IBD care. Psychotherapy has been found to offer a limited benefit for health related quality of life, coping, emotional state and disease activity in IBD population. Yet, cognitive-behavioural therapy (CBT), the most effective psychotherapy modality, has not been extensively investigated in IBD and the ongoing trials indicate its efficacy particularly with symptom management. Preliminary studies on antidepressants indicate their potential efficacy in treating mental health but also physical symptoms of the disease.
Conclusions: IBD sufferers commonly experience symptoms of anxiety and depression and they may have an impact on patient clinical outcomes. Regular screening for these co-morbidities is essential for good management. CBT shows promise in helping with somatic symptoms of IBD. More studies are needed on antidepressants specifically in IBD but they are overall well tolerated by patients and can be prescribed as per other populations. Disease extent of UC and CD was defined based on the Montreal Classification (E1 3 and L1 3, respectively). Vitamin D insufficiency was defined as a level below 15 and 30 ng/ml, deficiency was defined as a level under 15 ng/ml. Calculations were performed using SPSS statistics 15.0 software. Paired and independent sample Student's t-tests, Pearson correlations were applied. Results: Fifty-two percent of IBD patients had vitamin D insufficiency (CD: 53%, UC: 48%), 28% of them (CD: 25%, UC: 33%) had severe vitamin D deficiency. Only 20% of the IBD patients (CD: 22%, UC: 19%) had adequate vitamin D level (>30 ng/ml). The median vitamin D level was 22.74±10.61 ng/ml. Vitamin D levels did not differ regarding the type of the IBD (23.65±11.19 ng/ml vs. 19.89±7.66 in CD vs. UC; NS). There were no significant difference in vitamin D levels considering disease extent (CD-L1: 23.94±7.99 ng/ml, CD-L2: 23.79±8.62 ng/ml, CD-L3: 22.23±12.67 ng/ml; NS and UC-E1: 19.27±6.68 ng/ml, UC-E2: 19.60±6.54 ng/ml, UC-E3: 18.93±8.49 ng/ml; NS). Vitamin D concentration did not correlated neither to clinical activity indexes (partial Mayo score: r = 0.143; Crohn's disease activity index: r = 0.253) nor inflammatory parameters (C-reactive protein: r = 0.008; erythrocyte sedimentation rate: r = 0.012). Conclusions: Vitamin D deficiency is common in Hungarian patients with IBD. In contrast with results of previously performed studies, our results show that Vitamin D concentration is independent from disease extent or severity in IBD patients. However, methodological differences of Vitamin D determination, seasonal variation of blood sample taking and other important factors need to be considered while evaluating the different results. 
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